Recovery from hematopoietic injury by modulating prostaglandin E2 signaling post-irradiation

Blood Cells, Molecules, and Diseases

Volumn 50, Issue 3, 2013, Pages 147-153

  Hoggatt, Jonathan ^a   Singh, Pratibha ^a   Stilger, Kayla N ^a   Plett, P Artur ^a   Sampson, Carol H ^a   Chua, Hui Lin ^a   Orschell, Christie M ^a   Pelus, Louis M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hematopoietic stem cell; HS ARS; NSAID; Prostaglandin E2; Radiation

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

ACUTE RADIATION SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSIMETRY; DRUG EFFICACY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA RADIATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYNDROME OF ACUTE RADIATION SYNDROME; MALE; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; RADIATION EXPOSURE; SINGLE DRUG DOSE; THERAPY DELAY; TREATMENT OUTCOME;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME ACTIVATION; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; MALE; MICE; SIGNAL TRANSDUCTION; WHOLE-BODY IRRADIATION;

MUS;

EID: 84873277919     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.11.006     Document Type: Article

References (56)

1. Ahmed M., Khanna D., Furst D.E. Meloxicam in rheumatoid arthritis. Expert Opin. Drug Metab. Toxicol. 2005, 1:739-751.
2. Anno G.H., Baum S.J., Withers H.R., Young R.W. Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy. Health Phys. 1989, 56:821-838.
3. Asano S. Current status of hematopoietic stem cell transplantation for acute radiation syndromes. Int. J. Hematol. 2012, 95:227-231.
4. Broxmeyer H.E., Galbraith P.R., Baker F.L. Relationship of colony-stimulating activity to apparent kill of human colony-forming cells by irradiation and hydroxyurea. Blood 1976, 47:403-411.
5. Broxmeyer H.E., Mejia J.A., Hangoc G., et al. SDF-1/CXCL12 enhances in vitro replating capacity of murine and human multipotential and macrophage progenitor cells. Stem Cells Dev. 2007, 16:589-596.
6. Broxmeyer H.E., Smith S. Cord blood stem cell transplantation. Thomas' Hematopoietic Cell Transplantation 2009, 559-576. Wiley-Blackwell, Oxford. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
7. Cayeux S.J., Beverley P.C., Schulz R., Dorken B. Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. Bone Marrow Transplant. 1993, 12:603-608.
8. Chen X., Gresham A., Morrison A., Pentland A.P. Oxidative stress mediates synthesis of cytosolic phospholipase A2 after UVB injury. Biochim. Biophys. Acta 1996, 1299:23-33.
9. Chinsoo C.L., Glatstein E. Radiation Injury. Harrison's Principles of Internal Medicine 1998, 2559. McGraw-Hill, New York. A.S. Fauci, E. Braunwald, K.L. Isselbacher (Eds.).
10. Chitteti B.R., Kacena M.A., Srour E.F. Phenotypic characterization of hematopoietic stem cells. Cord Blood: Biology, Transplantation, Banking, and Regulation 2011, 75-85. AABB Press, Bethesda. H.A. Broxmeyer (Ed.).
11. Coleman C.N., Blakely W.F., Fike J.R., et al. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat. Res. 2003, 159:812-834.
12. Dainiak N., Waselenko J.K., Armitage J.O., et al. The hematologist and radiation casualties. Hematology. Am. Soc. Hematol. Educ.Program 2003, 473-496.
13. Fukuda S., Bian H., King A.G., Pelus L.M. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007, 110:860-869.
14. Gentile P., Byer D., Pelus L.M. In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2. Blood 1983, 62:1100-1107.
15. Gentile P.S., Pelus L.M. In vivo modulation of myelopoiesis by prostaglandin E2. II. Inhibition of granulocyte-monocyte progenitor cell (CFU-GM) cell-cycle rate. Exp. Hematol. 1987, 15:119-126.
16. Gentile P.S., Pelus L.M. In vivo modulation of myelopoiesis by prostaglandin E2. IV. Prostaglandin E2 induction of myelopoietic inhibitory activity. J. Immunol. 1988, 141:2714-2720.
17. Hall E.J. Radiobiology for the Radiologist 2000, Lippincott, Philadelphia. 5th edition.
18. Hanson W.R. Radiation protection of murine intestine by WR-2721, 16,16-dimethyl prostaglandin E2, and the combination of both agents. Radiat. Res. 1987, 111:361-373.
19. Hanson W.R., Ainsworth E.J. 16,16-Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells. Radiat. Res. 1985, 103:196-203.
20. Herodin F., Bourin P., Mayol J.F., et al. Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma -irradiation promotes survival. Blood 2003, 101:2609-2616.
21. Herodin F., Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp. Hematol. 2005, 33:1071-1080.
22. Hofer M., Pospisil M., Znojil V., et al. Meloxicam, a cyclooxygenase 2 inhibitor, supports hematopoietic recovery in gamma-irradiated mice. Radiat. Res. 2006, 166:556-560.
23. Hoggatt J., Singh P., Sampath J., Pelus L.M. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009, 113:5444-5455.
24. Isoherranen K., Punnonen K., Jansen C., Uotila P. Ultraviolet irradiation induces cyclooxygenase-2 expression in keratinocytes. Br. J. Dermatol. 1999, 140:1017-1022.
25. Jiao W., Kiang J.G., Cary L., et al. COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat. Res. 2009, 172:686-697.
26. Kargacin B., Kostial K. Reduction of 85Sr, 137Cs, 131I and 141Ce retention in rats by simultaneous oral administration of calcium alginate, ferrihexacyanoferrate(II), KI and Zn-DTPA. Health Phys. 1985, 49:859-864.
27. Kato M., Nishida S., Kitasato H., et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J. Pharm. Pharmacol. 2001, 53:1679-1685.
28. Kozubik A., Hofmanova J., Pospisil M., et al. Effects of drugs inhibiting prostaglandin or leukotriene biosynthesis on postirradiation haematopoiesis in mouse. Int. J. Radiat. Biol. 1994, 65:369-377.
29. Kurland J.I., Broxmeyer H.E., Pelus L.M., et al. Role for monocyte-macrophage-derived colony-stimulating factor and prostaglandin E in the positive and negative feedback control of myeloid stem cell proliferation. Blood 1978, 52:388-407.
30. Kurland J.I., Pelus L.M., Ralph P., et al. Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:2326-2330.
31. MacVittie T.J., Farese A.M., Jackson W. Defining the full therapeutic potential of recombinant growth factors in the post radiation-accident environment: the effect of supportive care plus administration of G-CSF. Health Phys. 2005, 89:546-555.
32. Moore A.H., Olschowka J.A., Williams J.P., et al. Regulation of prostaglandin E2 synthesis after brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:267-272.
33. Moulder J.E. Post-irradiation approaches to treatment of radiation injuries in the context of radiological terrorism and radiation accidents: a review. Int. J. Radiat. Biol. 2004, 80:3-10.
34. Nishiguchi I., Furuta Y., Hunter N., et al. Radioprotection of hematopoietic tissues in mice by indomethacin. Radiat. Res. 1990, 122:188-192.
35. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993, 81:2844-2853.
36. Pellmar T.C., Rockwell S. Priority list of research areas for radiological nuclear threat countermeasures. Radiat. Res. 2005, 163:115-123.
37. Pelus L.M. Blockade of prostaglandin biosynthesis in intact mice dramatically augments the expansion of committed myeloid progenitor cells (colony-forming units-granulocyte, macrophage) after acute administration of recombinant human IL-1 alpha. J. Immunol. 1989, 143:4171-4179.
38. Pelus L.M., Broxmeyer H.E., Kurland J.I., Moore M.A. Regulation of macrophage and granulocyte proliferation. Specificities of prostaglandin E and lactoferrin. J. Exp. Med. 1979, 150:277-292.
39. Pelus L.M., Broxmeyer H.E., Moore M.A. Regulation of human myelopoiesis by prostaglandin E and lactoferrin. Cell Tissue Kinet. 1981, 14:515-526.
40. Pelus L.M., Gentile P.S. In vivo modulation of myelopoiesis by prostaglandin E2. III. Induction of suppressor cells in marrow and spleen capable of mediating inhibition of CFU-GM proliferation. Blood 1988, 71:1633-1640.
41. Pelus L.M., Gold E., Saletan S., Coleman M. Restoration of responsiveness of chronic myeloid leukemia granulocyte-macrophage colony-forming cells to growth regulation in vitro following preincubation with prostaglandin E. Blood 1983, 62:158-165.
42. Pelus L.M., Hoggatt J. Pleiotropic effects of prostaglandin E2 in hematopoiesis; prostaglandin E2 and other eicosanoids regulate hematopoietic stem and progenitor cell function. Prostaglandins Other Lipid Mediat. 2011, 96:3-9.
43. Pelus L.M., Hoggatt J., Singh P. Pulse exposure of haematopoietic grafts to prostaglandin E2 in vitro facilitates engraftment and recovery. Cell Prolif. 2011, 44(Suppl. 1):22-29.
44. Pelus L.M., Ottmann O.G., Nocka K.H. Synergistic inhibition of human marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-alpha, -beta, and -gamma and an effect mediated by tumor necrosis factor. J. Immunol. 1988, 140:479-484.
45. Plett P.A., Sampson C.A., Chua H.L., et al. Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys. 2012, 103:343-355.
46. Pospisil M., Netikova J., Kozubik A., Pipalova I. Effect of indomethacin, diclofenac sodium and sodium salicylate on peripheral blood cell counts in sublethally gamma-irradiated mice. Strahlenther. Onkol. 1989, 165:627-631.
47. Poston J.W., Warren K. Sinclair keynote address: current challenges in countering radiological terrorism. Health Phys. 2005, 89:450-456.
48. Rinder H.M., Tracey J.B., Souhrada M., et al. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial. J. Clin. Pharmacol. 2002, 42:881-886.
49. Serushago B.A., Tanaka K., Koga Y., et al. Positive effects of indomethacin on restoration of splenic nucleated cell populations in mice given sublethal irradiation. Immunopharmacology 1987, 14:21-26.
50. Shaheen M., Broxmeyer H.E. The humoral regulation of hematopoiesis. Hematology: Basic Principles and Practice 2009, 253-275. Elsevier Churchill Livingston, Philadelphia. R. Hoffman, E.J.J. Benz, S.J. Shattil, B. Furie, L.E. Silberstein, P. McGlave, H. Heslop, J. Anastasi (Eds.).
51. Shi S., Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J. Clin. Pharmacol. 2008, 64:233-252.
52. Siegal T., Pfeffer M.R. Radiation-induced changes in the profile of spinal cord serotonin, prostaglandin synthesis, and vascular permeability. Int. J. Radiat. Oncol. Biol. Phys. 1995, 31:57-64.
53. Till J.E., McCulloch E.A. Repair processes in irradiated mouse hematopoietic tissue. Ann. N. Y. Acad. Sci. 1964, 114:115-125.
54. Wald N. Radiation Injury. Cecil Textbook of Medicine 1982, 2228. W.B. Saunders, Philadelphia. J.B. Wyngaarden, L.H.J. Smith (Eds.).
55. Walden T.L., Farzaneh N.K. Radioprotection by 16,16 dimethyl prostaglandin E2 is equally effective in male and female mice. J. Radiat. Res. (Tokyo) 1995, 36:1-7.
56. Walden T.L., Patchen M., Snyder S.L. 16,16-Dimethyl prostaglandin E2 increases survival in mice following irradiation. Radiat. Res. 1987, 109:440-448.